Hyderabad, Telangana, India, January 2025 – Kunal Botadra has joined Suven Pharmaceuticals as the Chief M&A Officer, bringing his extensive expertise in mergers and acquisitions, strategic planning, and business transformation. In his new role, Kunal will oversee Suven Pharma’s M&A strategies, ensuring alignment with the company’s vision for growth and global expansion in the pharmaceutical sector.
Kunal most recently served as the Founder of SteadMount Capital Advisors, where he provided strategic M&A advisory services for nearly two years. Concurrently, he was a Strategy and M&A Advisor at Curium Pharma, contributing to the company’s growth initiatives.
Prior to this, Kunal was the Head of Mergers and Acquisitions at Advent API Platform, where he led several high-impact M&A transactions. During his tenure, he demonstrated his ability to identify synergies and execute strategies effectively, enhancing the company’s value proposition.

Kunal also held leadership roles at Tata Consumer Products, where he served as Director of Business Integration and Transformation and DGM – Strategy and M&A. He played a pivotal role in the demerger of Tata Chemicals’ consumer products business into Tata Global Beverages and executed strategic initiatives, including market expansions and divestitures.
His earlier experience includes Mergers & Acquisitions at Cipla Ltd., where he successfully closed multiple transactions, and Vice President, Healthcare Investment Banking at Royal Bank of Scotland, where he managed M&A and strategic financing mandates across Europe.
About Suven Pharmaceuticals
Suven Pharmaceuticals is a leading contract drug development and manufacturing services (CRAMS) partner with over 33 years of expertise in research, innovation, and quality. The company operates across India and the USA, serving more than 25 global clients with stringent regulatory requirements. Suven Pharmaceuticals offers comprehensive solutions across the CRAMS value chain, backed by a team of 400+ scientists, including 35 PhD holders, and USFDA-audited facilities.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning